Ascendis Pharma A/S announced that the company has entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan. Under the terms of the agreement, Ascendis will receive an upfront payment of $70 million, with additional development and regulatory milestones of up to $175 million, transfer pricing and commercial milestones. In addition, Ascendis Pharma is eligible to receive royalties on net sales in Japan, of up to mid-20's percent, varying by product.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
136 USD | +1.48% | -1.78% | +7.96% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,538 JPY | +0.13% | -0.29% | 1.91B | ||
136 USD | +1.48% | -1.78% | 7.77B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.96% | 7.77B | |
+10.44% | 107B | |
+0.82% | 106B | |
+6.72% | 23.47B | |
-13.89% | 21.9B | |
-6.64% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B |
- Stock Market
- Equities
- ASND Stock
- News Ascendis Pharma A/S
- Ascendis Pharma A/S Announces Strategic Partnership with Teijin Limited in Japan